Interesting to see differences in the recipients and what they received.
"Both vaccines elicited a robust antibody response, but median signal was higher in Moderna recipients. Symptom severity decreased with age. Antibody response in Pfizer recipients negatively correlated with age."
Seems to show effectiveness of the IP as well
"Observations of increased non-RSV hospitalization rates among RSV IP recipients in some non-randomized studies could be primarily explained by differences in the clinical characteristics between RSV IP recipients and controls."
Good to see the current evidence especially during the flu season. Shows a room for progress for a shot that could be universal.
"...so far no differences have been found in cardiopulmonary outcomes between a high-dose trivalent and a standard-dose quadrivalent vaccine in patients hospitalized for acute MI or heart failure."
We see the importance in safety and exercising a level of caution for individuals of any age, especially the young individuals and assessing symptoms is vital.
I would think that may be consistent with evidence.
"patients returning to their physical activities before full resolution of symptoms are at higher risk of persistent symptoms and further injury."
论文